Skip to main content
. 2023 Feb 25;43(5):951–964. doi: 10.1007/s10875-022-01426-y

Fig. 7.

Fig. 7

Presence of anti-drug antibodies during elapegademase therapy. Based on test results for first tier (“immunoggenicity” in source listing) and second tier (“immuno-2” in source listing; performed only if first-tier result was positive)